Covid-driven biotech and healthcare run set to continue for investors with high risk tolerance
Home / Analysis / Covid-driven biotech and healthcare run set to continue for investors with high risk tolerance Covid-driven biotech and healthcare run set to continue for investors with high risk tolerance Schroder Global Healthcare and Axa Framlinton Health Care have returned 519% and 289% over the past decade The biotech and healthcare sectors have flourished during the pandemic as companies raced to develop a Covid-19 vaccine. Those already invested have reaped the rewards, but what next? Is it time to reconsider this exposure or is there more to come? Data from Grand View Research forec...
Source: portfolio-adviser.com